Monitor for announcement of the trial partner and specific indication, which could clarify revenue potential. The export validates Optimi's GMP supply chain and regulatory pathway, but near-term revenue is uncertain. Watch for follow-on clinical trial supply contracts or expansion into additional European markets.
Price Chart
Executive Summary
Optimi Health Corp. announced its first export of naturally derived psilocybin (biomass and 5mg capsules) to the UK to support a planned Phase 2 clinical trial. The shipment was authorized by Health Canada and the UK Home Office, and the product uses the same formulation already prescribed in Australia for treatment-resistant depression. This is a commercial milestone for Optimi as a vertically integrated GMP supplier, but the trial partner, indication, and revenue impact remain undisclosed.
Key Facts
- First export of psilocybin to the UK for a planned Phase 2 clinical trial.
- Shipment includes psilocybin biomass and finished 5mg capsules.
- Product manufactured at Optimi's GMP facility in Princeton, British Columbia.
- Export authorized by Health Canada and UK Home Office.
- Same formulation currently prescribed to patients in Australia for treatment-resistant depression.
- Trial partner and indication to be announced at a later date.
Financial Impact
No financial figures disclosed; revenue impact from this export is not quantifiable from the filing.
Risk Factors
- Trial partner and indication not yet announced, creating uncertainty about commercial scale.
- No revenue or financial terms disclosed for this shipment.
- Forward-looking statements subject to regulatory and clinical trial risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-265161 |
| Document: d126955d6k.htm | 0001193125-26-265161 |
| Document: 0001193125-26-265161-index-headers.html | 0001193125-26-265161 |
| Document: 0001193125-26-265161-index.html | 0001193125-26-265161 |
| Document: 0001193125-26-265161.txt | 0001193125-26-265161 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $3.36 | awaiting T+5 | — | $3.28 (−2.53%) |
Oct 20, 2026 6d ago | 6-K | $3.36 | awaiting T+5 | — | $3.28 (−2.53%) |
Oct 7, 2026 19d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.28 (−18.94%) |
Oct 5, 2026 20d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.28 (−20.70%) |
Sep 29, 2026 27d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.28 (−31.49%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.28 (−33.97%) |
Sep 22, 2026 4w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.28 (−33.97%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.28 (−33.16%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.28 (−27.22%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.28 (+33.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers